Introduction
Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures [1, 2] . These seizures are transient signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain [3] . About 50 million people worldwide suffer from epilepsy, with almost 90% of these people living in developing countries [4] . It is noteworthy that, many of the current antiepileptic drugs were developed empirically on the basis of their activity in animal models. The mechanism of action of these drugs at the cellular level is not fully understood. However, the ultimate goal of the antiepileptic is to prevent the paroxysmal discharge without affecting normal transmission [5] .
A myriad of pyrrolidine derivatives cover a great section of the Medicinal Chemistry drug armamentarium. These compounds display a broad spectrum of pharmacodynamic and chemotherapeutic profiles [6] . Among these, are the compounds that display anticonvulsant activities [7] [8] [9] [10] [11] [12] [13] [14] [15] .
Previously, we have reported the anticonvulsant properties of certain pyrrolidine surrogates (IIII) [16] [17] [18] that showed anticonvulsant activities at dose levels of 0.07, 0.04 and 0.01 mmol/kg b.wt. equivalent to 30, 15 and 3.97 mg/kg body weight (b.wt.), respectively.
Thus, in continuation to our work in this field it was of interest to design and synthesize four series of pyrrolidine derivatives related to structures of IIII namely: 1-acetyl-4-hydroxy-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carbo xylic acids (3ae, Scheme 1), 1-H-4-hydroxy-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acids (4ae, Scheme 1), 1-acetyl-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carbo xylic acids (8ae, Scheme 2), 1-H-5-benzyl or 5-(4-alkoxybenzyl)-pyrrolidine-3-carboxylic acids (9ae, Scheme 2) to be pharmacologically screened for their anticonvulsant activities. These compounds bear the pyrrolidine-3-carboxylic acid ring structure which may be considered as a rigid cyclized form of γ-aminobutyric acid (GABA), which acts as an important inhibitory neurotransmitter in the central nervous system. Similar ring system is also found in the anticonvulsants gamibetal [19] , gabapentin [20] and baclofen [21] (Figure 1 ).
Experimental

Chemistry
All melting points are uncorrected and were determined with Electrothermal Capillary melting point apparatus. Infrared (IR) spectra were recorded as thin film (for oils) in NaCl discs or as KBr pellets (for solids) with JASCO FT/IR-6100 Spectrometer and values are represented in cm -1 . 1 H NMR and 13 C NMR spectra were recorded on Jeol ECA 500 MHz Spectrophotometer using TMS as internal standard and chemical). The shift values are reported in ppm ( 1 H NMR data were represented as follows: chemical shifts, multiplicity (s. singlet, d. doublet, t. triplet, q. quartet, m. multiplet, and br. broad) and number of protons. The 13 C NMR data were represented as chemical shifts and type of carbon, the chemical shifts bearing "*" could be interchanged. The mass spectra were recorded on Finnigan Mat SSQ-7000 Spectrophotometer and Jeol JMS-AX 500. Elemental analyses were carried out at the Microanalytical Unit, National Research Centre, Cairo, Egypt. Aluminium oxide 60G F254 neutral plates for TLC (Merck) were used for thin layer chromatography. Visualization was performed by illumination with UV light source (254 nm). Column chromatography was performed with alumina neutral III for gravity columns. The solvent system used in column elution was: Petroleum-ether (40-60 o C): ethyl acetate (9:1). The compounds throughout this work were named according to AutoNom® computer program version 2.1, MDL Information Systems, as component of Chemdraw Ultra® program package version 5. Synthesis of 1-acetyl-4-ethoxycarbonyl-2-benzyl or 2-(4-alkoxy-benzyl)-pyrrolidin-3-one (1ae) [22, 23] and 1-acetyl-4-hydroxy-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acid ethyl esters (2ae) [24] was performed according to the reported procedures. Structural relation between γ-aminobutyric acid (GABA), Gamibetal, Gabapentin, Baclofen and the target compounds, 3a-e, 4a-e, 8a-e and 9a-e.
General procedure for preparation of 1acetyl4 hydroxy5benzyl or 5(4alkoxybenzyl)pyrrolidine3 carboxylic acid (3ae)
To 0.0143 mol of 2ae in ethanol (15 mL), 14.3 mL of lithium hydroxide solution (1.7 N) was added. The reaction mixture was stirred for 24 h at room temperature and evaporated under reduced pressure. The residue was dissolved in water and washed with ethyl acetate. The aqueous layer was acidified with hydrochloric acid (1 N), extracted with ethyl acetate, dried and evaporated under reduced pressure to afford 3a-e as solids which were recrystallized from isopropanol. To 0.0034 mol of the 1-acetyl-4-hydroxy-5-benzyl or -5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acid (3ae) was added 7 mL of hydrochloric acid solution (5 N). The reaction mixture was refluxed for 5 h, then evaporated under reduced pressure and crystallized from ethyl acetate /alcohol (9:1) to afford the hydrochloride salts 4ae as solids (Scheme 1). 
1H4Hydroxy5(4npropoxybenzyl)pyrrolidine 3carboxylic acid hydrochloride (4d)
Yield 81% decomposition at 270 o C. IR (KBr, cm -1 ) 3228-2764 ( br, OH alcohol and acid) and 1716 (C=O, acid ). 1 
General procedure for preparation of 1acetyl5 benzyl or 5(4alkoxybenzyl)pyrrolidine3carboxylic acid ethyl esters (7ae)
A solution of 0.01 mol of 1-acetyl-4-hydroxy-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acid ethyl ester (2ae) in 9.4 mL (10.2 g, 0.1 mol) of acetic anhydride was refluxed for 18h. The reaction mixture was evaporated under vacuum, diluted with water and extracted with ethyl acetate (2x50 mL). The organic layers were shaken with 10% solution of sodium hydrogen carbonate (2x50 mL) then with water (1x50 mL). The organic layer was dried (MgSO4) and evaporated under vacuum to afford 4-acetoxy-1-acetyl-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acid ethyl esters (5ae) as brown oils, which were used as such in the next step. The yields of 5ae were: 80%, 86%, 82%, 78% and 90%, respectively. The IR (liquid film, cm 1 ) spectra of 5ae showed bands at 1725-1747 (C=O, acetoxy and ester), 1644-1651 (C=O, amide) and absence of OH band at 3325-3335 cm -1 .
Scheme 2
A solution of 0.01 mol of 5ae in 30 mL of freshly distilled tetrahydrofuran was stirred at room temperature for 2-3h in the presence of 1.49 mL (1.52 g, 0.01 mol) of 1,8-diazabicyclo-[5.4.0]undec-7-ene (DBU). The reaction mixture was evaporated under vacuum. The residue was diluted with water, acidified with hydrochloric acid (1 N) and extracted with diethyl ether (3x25 mL). The organic layers were separated, dried (MgSO4) and evaporated under vacuum to afford 1-acetyl-5-benzyl or 5-(4-alkoxy-benzyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid ethyl ester (6ae) as yellowish brown oils, which were pure enough to be used in the next step. The yields of 6ae were: 78%, 80%, 67%, 82% and 81%, respectively.
A solution of 0.01 mol of 1-acetyl-5-benzyl or 5-(4-alkoxybenzyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid ethyl ester (6ae) in 150 mL of ethanol 95% was hydrogenated at room temperature and normal pressure for 48 h, using 0.23 g (0.001 mol) of platinum IV oxide. Then, the catalyst was filtered off and ethanol was evaporated under vacuum to afford 1-acetyl-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acid ethyl esters (7ae) as yellow oils, which were purified by column chromatography using petroleum-ether (40-60 o C): ethyl acetate (9:1). 
1Acetyl5benzylpyrrolidine3carboxylic acid ethyl ester (7a)
Yield
General procedure for preparation of 1H5benzyl or 5(4alkoxybenzyl)pyrrolidine3carboxylic acid hydrochlorides (9ae)
To 0.0034 mol of N-acetylated-4-hydroxy-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acid (8ae) was added 7 mL solution of hydrochloric acid (5 N). The reaction mixture was refluxed for 5 h, evaporated under reduced pressure to afford the hydrochlorides 9ae as solids which were crystallized from ethyl acetate/ alcohol (9:1). The anticonvulsant activity of the target compounds 3ae, 4ae, 8ae and 9ae was tested on adult male Swiss albino mice weighing 18-35 g. Animals were obtained from Animals House Colony of the National Research Centre, Cairo, Egypt. All animals were allowed free access to water and kept at constant diet.
1H5Benzylpyrrolidine3carboxylic acid hydrochloride (9a)
Chemicals and drugs
Tween 80 (Sigma, USA), Pentylenetetrazole (Sigma,USA) and Gabapentin (Neurontin®; Parke Davis, USA) were used in this study. All the tested compounds were dissolved in 7% tween-80 saline solutions.
Determination of the anticonvulsant activity using Subcutaneous pentyleneteterazole seizures (scPTZ) test
Experiments [25, 26] were carried out with groups of (6-10) mice each. The first group was divided into 3 subgroups and received intraperitoneally (ip) gabapentin (0.084, 0.14 and 0.28 mmol/kg b.wt equivalent to 15, 25, 50 mg/kg b.wt., respectively) [27] as reference drug. The second group was divided into 20 subgroups, each of which received (ip) one of the tested compounds 3a-e, 4a-e, 8a-e and 9a-e at dose levels of 0.0087, 0.0174, 0.0261, 0.05, 0.059 and 0.065 mmol / kg b.wt. One hour later [26] pentylenetetrazole (85 mg/kg) was administered (sc). The minimum dose of compounds and reference standard that induced maximum % protection was evaluated. The absence of seizures was chosen as an index for protective effect against pentylenetetrazole induced seizures as shown in Tables 1, 2 , 3 and 4.
Results and Discussion
Chemistry
The starting synthon for the preparation of 1-acetyl 4-hydroxy-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carbo xylic acid ethyl esters (2ae, Scheme 1) is the -ketoesters 1-acetyl-4-ethoxycarbonyl-2-benzyl or-2-(4-alkoxy-benzyl) pyrro lidin-3-ones (1ae) [22, 23] . The latter underwent hydro genation at room temperature and normal pressure using platinum IV oxide as a catalyst in ethanol (95%) to afford 2ae [24] .
Subsequent hydrolysis of pyrrolidine esters 2ae using lithium hydroxide solution (1.7 N) gave the corresponding acids 3ae in 73-85% yields (c.f. Experimental). Their structures were confirmed through infrared, NMR, mass spectroscopy and microanalytical data. Deacetylation of 3ae was achieved by refluxing with hydrochloric acid (5 N) for 5h to afford the hydrochloride salts 4ae in 76-85% yields (c.f. Experimental). The Synthetic pathway for preparation of 1-acetyl-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acids (8ae) was performed according to the previously reported procedure of Aboul-Enein et al. [18] (Scheme 2) in 80-90% yields. Subsequent deacetylation by stirring solutions of 5ae in tetrahydrofuran in the presence of 1, 8-diazabicyclo [5.4 .0] undec-7-ene (DBU) resulted in the double bond formation between C-3 and C-4 in the pyrrolidine ring to afford 6ae in good yields. Catalytic hydrogenation of the pyrroline double bond of compounds 6ae by platinum IV oxide in ethanol (95%) under room temperature and normal pressure for 48h gave 1-acetyl-5-or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acid ethyl esters (7ae) in quantitative yields (c.f. Experimental). Subsequent hydrolysis of the esters 7ae was performed using lithium hydroxide solution (1.7 N) to give the corresponding 1-acetyl-5-benzyl or 5-(4-alkoxybenzyl)-pyrrolidine-3-carboxylic acids (8ae) as solids in good yields. Their structures were confirmed through infrared, NMR, mass spectroscopy and microanalytical data (c.f. Experimental). The target compounds 9ae were achieved through refluxing 8ae with hydrochloric acid (5N) to afford the hydrochlorides 9ae as solids in good yields (c.f. Experimental).
Pharmacology
Compounds 3ae, 4ae, 8ae and 9ae were evaluated for their anticonvulsant potential using subcutaneous pentylen etetrazole seizures (scPTZ) test and gabapentin as a reference drug. The anticonvulsant activity of 1-acetyl-4-hydroxy-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acids series (3ae, Table 1 ) was screened. The data presented in Table 1 illustrated that compounds 3a, 3c and 3d are the most active of the series and exhibited equipotent anticonvulsant potential of 84% protection against pentylenetetrazole seizures at dose level of 0.065mmol/kg b.wt. The anticonvulsant potential of the different congeners of this series is arranged in the following decreasing order: 3a= 3c =3d >3e > 3b. Table 1 . Anticonvulsant activity of 1-acetyl-4-hydroxy-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acids (3ae) using sc PTZ-induced seizures in adult male albino mice. Also, the anticonvulsant potential of 1-H-4-hydroxy-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acid hydro chlorides (4ae, Table 2) showed that compound 1-H-4-hydroxy-5-(4-methoxy-benzyl)-pyrrolidine-3-carboxylic acid hydrochloride (4b) possessed 100% protection against pentylenetetrazole seizures at dose level of 0.0087 mmol/kg b.wt., meanwhile compounds 1-H-4-hydroxy-5-(4-ethoxybenzyl)-pyrrolidine-3-carboxylic acid hydrochloride (4c) and 1-H-4-hydroxy-5-(4-propoxy-benzyl)-pyrrolidine-3-carboxylic acid hydrochloride (4d) showed equipotent protection activity of 84% at dose level of 0.0261 mmol/kg b.wt. On the other hand, compound 4a (0.0261 mmol/kg b.wt.) displayed 72% protection level compared with gabapentin (0.14 mmol/kg b.wt.). The different congeners of this series showed a decrease in the anticonvulsant potential in the following order: 4b> 4c= 4d > 4a>4e (c.f. Table 2 ). The anticonvulsant profile of 1-acetyl-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acids series (8ae ,  Table 3 ) showed that compound 8d displayed 100% protection at dose level of 0.05mmol/kg b. wt., nearly 3-fold more potent than the reference drug gabapentin (0.14 mmol/kg b. wt.), while 8b and 8e exhibited 84% protection potential at dose level of 0.05 and 0.065 mmol/kg b.wt., respectively. Meanwhile 8c showed 67% protection at dose level of 0.065 mmol/kg b.wt. On the other hand, 1-acetyl-5-benzyl-pyrrolidine-3-carboxylic acid (8a) gave 33% protection at dose level of 0.05 mmol/kg b.wt. compared with gabapentin (0.14 mmol/kg b.wt.). The anticonvulsant potential for the different congeners showed the following decreasing order: 8d >8b >8e >8c >8a. Table 3 . Anticonvulsant activity of 1-acetyl-5-benzyl or 5-(4-alkoxybenzyl)-pyrrolidine-3-carboxylic acids (8ae) using sc PTZ-induced seizures in adult male albino mice. Also, the results of the anticonvulsant activity of 1-H-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acid hydrochlorides (9ae, Table 4) showed that compound 1-H-5-(4-butoxy-benzyl)-pyrrolidine-3-carboxylic acid hydrochloride (9e) exhibited 100% protection at dose level of 0.0261 mmol/kg b.wt., while compounds 9ad exerted 72, 67, 67 and 63% protection, respectively at the same dose (0.0261 mmol/kg b.wt.) as compared with gabapentin (0.14 mmol/kg b.wt.). The different congeners of this series showed anticonvulsant potential in the following decreasing order: 9e >9a> 9b =9c >9d. 
Compound
Structureactivity relationship
Regarding the structure-activity relationship of the target compounds, the results revealed that the 1-H-4-hydroxy-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acid hydrochlorides (4ae) series showed higher anticonvulsant activity than the other series 3ae, 8ae and 9ae as well as the reference standard. The most potent of series 4ae is compound 4b which exhibited 100% protection at dose level of 0.0087mmol/kg b.wt. which is about 16-fold that of gabapentin. Moreover, compound 4b exhibited higher potency than our previously reported compounds IIII [16] [17] [18] . Two compounds 4c, 4d showed 84% protection, one compound 4a exhibited 72% and the compound 4e exhibited 67% protection. In series 4ae, it could be deduced that the presence of the carboxylic, hydroxyl and the free pyrrolidine amino groups all together, in one and the same compound, is a requirement to achieve potent anticonvulsant potential. Mostly, the substitution of the phenyl ring at the 4-position with an alkoxy group resulted in a better activity than the unsubstituted one. Meanwhile, the presence of acetyl group in 1-acetyl-4-hydroxy-5-benzyl or 5-(4-alkoxy-benzyl)-pyrrolidine-3-carboxylic acid series 3ae, resulted in a decrease in the anticonvulsant potential than series 4ae. The presence of the acetyl group in series 8ae led to a decrease in the anticonvulsant activity relative to series 9ae. Within the same series 8ae, the substitution of the phenyl ring resulted in increasing the anticonvulsant activity. Meanwhile, the absence of hydroxyl group in series 9ae resulted in a decrease in the anticonvulsant activity relative to series 4ae.
